dani@drughunter.com
Recent Articles by Dani
ACS Fall 2023 First Disclosures
The First Disclosures sessions at the 2023 ACS Fall Meeting in San Francisco, organized by Nikki Goodwin, presented a variety of new orally available small molecules. The standing room-only sessions were so highly attended that many attendees were unfortunately kicked out due to the fire code. In case you missed any of these exciting molecules,…
Molecules of the Month – July 2023
This month features big announcements from Biogen on their acquisition of Reata and their Nrf2 activator for Friedreich’s ataxia and from BridgeBio on their TTR stabilizer with positive Ph. III data for their ATTR-CM treatment. A pair of KRAS inhibitors from Chugai (macrocycle) and AstraZeneca (brain-penetrant) also makes the list for their notable pharmacology. Other…
Molecules of the Month – June 2023
With the popular success of diabetes and weight-loss peptide drugs from Novo (e.g. semaglutide/Ozempic), this month features a pair of ultra-hot non-peptide oral GLP-1R modulators in clinical development. Other notable Molecules of the Month include vorasidenib, which demonstrated headline-generating efficacy in brain cancers, as well as controversial billion-dollar molecule atrasentan, the subject of a short-seller…
Drug Hunter Journal Club: April 2023
We couldn’t include everything in Molecules of the Month, but here’s a round-up of up of 16 additional molecules of potential interest that we didn’t have space for in April, including a highly selective caspase inhibitor from a non-catalytic cysteine, a GPR40 AgoPAM from BMS with activity on GLP-1, a few examples of both on-…
A Cross-Functional Mindset in DMPK
Dian Su’s journey from chemistry and proteomics to the DMPK of drug conjugates Following a different path comes naturally to Dian Su, Senior Director of DMPK at Bicycle Therapeutics. From a childhood in a small village in China’s northeast Shandong province to her work examining the drug metabolism and pharmacokinetics (DMPK) of antibody-drug conjugates (ADCs)…
Molecules of the Month – April 2023
An oral macrocyclic peptide PCSK9 inhibitor entering Ph. III for hypercholesterolemia later this year, a Ph. I/Ib KRASG12C(ON) tri-complex inhibitor for the treatment of advanced solid tumors, an oral mutant-selective BRAFC600X degrader in Ph. I for BRAF-driven cancers, and an orally available AR-degrading PROTAC in Ph. II for advanced prostate cancers are just some of…